Beigene LtdNASDAQ:BGNE
- LAST PRICE187.6900
- TODAY'S CHANGE (%)-1.5400 (-0.8138%)
- Bid / Lots160.0000/ 1
- Ask / Lots208.5600/ 1
- Open / Previous Close186.9200 / 189.2300
- Day Range
- 52 Week Range
- Volume444,597
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BGNE |
|---|---|---|
| 09:32 ET | 3587 | 186.92 |
| 09:33 ET | 500 | 187.6 |
| 09:39 ET | 300 | 185.8738 |
| 09:42 ET | 200 | 186 |
| 09:44 ET | 100 | 185.93 |
| 09:46 ET | 138 | 185.945329 |
| 09:48 ET | 100 | 186.21 |
| 09:50 ET | 200 | 185.92 |
| 09:51 ET | 617 | 184.49 |
| 09:53 ET | 407 | 184.62 |
| 09:55 ET | 300 | 185.51 |
| 10:00 ET | 100 | 184.795 |
| 10:02 ET | 100 | 185.84 |
| 10:06 ET | 600 | 185.45 |
| 10:11 ET | 2500 | 185.9 |
| 10:13 ET | 758 | 185.94 |
| 10:15 ET | 400 | 185.93 |
| 10:18 ET | 862 | 185.2 |
| 10:20 ET | 200 | 185.51 |
| 10:26 ET | 100 | 186.5 |
| 10:29 ET | 215 | 186 |
| 10:31 ET | 2050 | 186.59 |
| 10:36 ET | 100 | 187.41 |
| 10:38 ET | 600 | 187.33 |
| 10:44 ET | 800 | 186.45 |
| 10:47 ET | 500 | 186.2 |
| 10:51 ET | 100 | 186.215 |
| 10:54 ET | 1139 | 186.47 |
| 10:56 ET | 5607 | 186.431 |
| 10:58 ET | 300 | 186.22 |
| 11:02 ET | 100 | 186.275 |
| 11:14 ET | 200 | 186.255 |
| 11:18 ET | 661 | 186.69 |
| 11:21 ET | 400 | 186.635 |
| 11:30 ET | 200 | 186.98 |
| 11:45 ET | 1300 | 186.155 |
| 11:48 ET | 800 | 185.65 |
| 11:50 ET | 100 | 185.34 |
| 11:56 ET | 100 | 185.655 |
| 12:01 ET | 815 | 186.3 |
| 12:03 ET | 875 | 186.24 |
| 12:06 ET | 100 | 186.51 |
| 12:10 ET | 3100 | 186.92 |
| 12:12 ET | 583 | 186.91 |
| 12:17 ET | 100 | 186.91 |
| 12:19 ET | 100 | 186.82 |
| 12:26 ET | 2253 | 186.5 |
| 12:28 ET | 535 | 186.48 |
| 12:30 ET | 767 | 186.72 |
| 12:39 ET | 300 | 186.94 |
| 12:42 ET | 100 | 186.86 |
| 12:50 ET | 100 | 186.86 |
| 12:51 ET | 134 | 186.66 |
| 12:57 ET | 100 | 186.57 |
| 01:00 ET | 100 | 186.64 |
| 01:02 ET | 2449 | 186.88 |
| 01:11 ET | 100 | 186.9 |
| 01:13 ET | 100 | 186.92 |
| 01:22 ET | 100 | 186.86 |
| 01:29 ET | 300 | 186.44 |
| 01:33 ET | 100 | 186.655 |
| 01:36 ET | 200 | 186.59 |
| 01:38 ET | 100 | 187.015 |
| 01:42 ET | 100 | 187.1 |
| 01:51 ET | 100 | 186.58 |
| 01:54 ET | 817 | 186.5 |
| 01:56 ET | 200 | 186.73 |
| 02:03 ET | 10566 | 186.54 |
| 02:05 ET | 5222 | 186.65 |
| 02:07 ET | 500 | 187.11 |
| 02:16 ET | 1247 | 186.79 |
| 02:18 ET | 513 | 186.7676 |
| 02:21 ET | 100 | 186.89 |
| 02:23 ET | 300 | 186.65 |
| 02:36 ET | 100 | 186.4845 |
| 02:39 ET | 400 | 186.46 |
| 02:43 ET | 400 | 187.005 |
| 02:52 ET | 320 | 187.235 |
| 03:01 ET | 238 | 187.27 |
| 03:15 ET | 300 | 187.47 |
| 03:17 ET | 457 | 187.07 |
| 03:19 ET | 400 | 187.27 |
| 03:21 ET | 3268 | 186.87 |
| 03:24 ET | 200 | 187.11 |
| 03:26 ET | 856 | 187.63 |
| 03:28 ET | 200 | 187.63 |
| 03:30 ET | 100 | 187.63 |
| 03:32 ET | 3416 | 187.63 |
| 03:33 ET | 1110 | 187.37 |
| 03:35 ET | 200 | 187.25 |
| 03:37 ET | 1000 | 187.25 |
| 03:39 ET | 1884 | 187.76 |
| 03:42 ET | 1690 | 187.905 |
| 03:44 ET | 220 | 188.02 |
| 03:46 ET | 1182 | 187.86 |
| 03:48 ET | 200 | 188.04 |
| 03:50 ET | 840 | 187.925 |
| 03:51 ET | 1260 | 188.16 |
| 03:53 ET | 1220 | 188.245 |
| 03:55 ET | 2520 | 188.12 |
| 03:57 ET | 2126 | 188.27 |
| 04:00 ET | 15286 | 187.69 |
Nov 14, 2024
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer, from 6:00AM ET on Thursday Nov 14, 2024 by Dow Jones
6:00AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
DJ BeiGene Is Maintained at Buy by TD Cowen, from 1:11PM ET on Wednesday Nov 13, 2024 by Dow Jones
1:11PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
*DJ BeiGene 3Q Rev $1B >BGNE, from 6:01AM ET on Tuesday Nov 12, 2024 by Dow Jones
6:01AM ET on Tuesday Nov 12, 2024 by Dow JonesBeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates, from 6:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
6:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 6, 2024
BeiGene to Present at the Jefferies London Healthcare Conference, from 6:01AM ET on Wednesday Nov 06, 2024 by Dow Jones
6:01AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beigene Ltd | 20.7B | -22.8x | --- |
United Therapeutics Corp | 16.0B | 15.8x | +8.22% |
BioMarin Pharmaceutical Inc | 11.8B | 37.2x | --- |
Exact Sciences Corp | 9.2B | -42.3x | --- |
Neurocrine Biosciences Inc | 11.9B | 31.5x | +62.04% |
Incyte Corp | 14.8B | 550.0x | +39.11% |
Company Information
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Contact Information
- Headquarters
- C/O Mourant Governance Services (Cayman) 94 Solaris Avenue, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108
- Phone
- 345-949-4123
- Fax
- ---
Executives
- Co-Founder, Executive Chairman of the Board, Chief Executive Officer
- John Oyler
- President, Chief Operating Officer, General Manager - China
- Xiaobin Wu
- Co-Founder, Non-Executive Director
- Xiaodong Wang
- Chief Financial Officer
- Aaron Rosenberg
- Senior Vice President, General Counsel
- Chan Lee
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $20.7B |
|---|---|
Revenue (TTM) | $3.3B |
Shares Outstanding | 106.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.56 |
EPS | $-8.24 |
Book Value | $36.95 |
P/E Ratio | -22.8x |
Price/Sales (TTM) | 6.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -26.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
